chrisvoncsefalvay/vaers-outcomes huggingface dataset:
at his workplace, one of the technicians tested positive; my allergies seem to be in my head; headache; My arm was a little sore too.; my eyes very red; eye watering and nasal congestion; eye watering and nasal congestion; This is a spontaneous report from a contactable consumer (patient). A 49-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection, Lot Number: not reported), via an unspecified route of administration on an unspecified date (at the age of 49 years) as dose 1, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient reported, after 4 days of first dose he had eyes watering and nasal congestion on 01Apr2021. It was like he was having allergies. At his workplace, one of the technicians tested positive, he felt like allergies seem to be in his head and between his eyes and he had a headache. His arm was a little sore too. He was feeling tiredness (not clear, hence not captured as event) his eyes very red, like allergy symptoms like that. The clinical outcome of the events lacrimation increased and nasal congestion was not recovered; unknown for the rest of the events.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Mother noticed redness and swelling of left upper arm near shoulder 09/13/2001 PM. Area is red, swollen, warm to touch. Child denies discomfort.
Histamine reaction/Itching from head to toe; Can not sleep at night; Injection site was warm; Itchy Injection site; Injection site was swollen; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Histamine reaction/Itching from head to toe), INSOMNIA (Can not sleep at night), VACCINATION SITE WARMTH (Injection site was warm), VACCINATION SITE PRURITUS (Itchy Injection site) and VACCINATION SITE SWELLING (Injection site was swollen) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Sulfonamide allergy (Allergic to Sulfa), Cancer and Diabetes.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In August 2021, the patient experienced PRURITUS (Histamine reaction/Itching from head to toe), INSOMNIA (Can not sleep at night), VACCINATION SITE WARMTH (Injection site was warm), VACCINATION SITE PRURITUS (Itchy Injection site) and VACCINATION SITE SWELLING (Injection site was swollen). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Itching, at a dose of 1 dosage form and PREDNISONE for Itching, at a dose of 1 dosage form. In August 2021, VACCINATION SITE WARMTH (Injection site was warm) and VACCINATION SITE SWELLING (Injection site was swollen) had resolved. At the time of the report, PRURITUS (Histamine reaction/Itching from head to toe) and VACCINATION SITE PRURITUS (Itchy Injection site) had not resolved and INSOMNIA (Can not sleep at night) outcome was unknown.            It was reported that as long as the patient takes Benadryl, the itching stopped but when the patient stopped taking Benadryl, the itching came back. Patient stated that her 70-year old brother and 55 year old sister having same reaction with third dose were all allergic to sulfa. Patient was not sure if the third dose was administered in the muscle.   No concomitant medications were reported   This case was linked to MOD-2021-046381 (Patient Link).
Pain at injection site during evening and next day; next morning approximately 16 hours after injection after a light breakfast, I fainted.  Additionally, I had profuse sweating observed after fainting.  In general, I experienced a feeling of fatigue.
got kind of red around the shot area after getting the second booster; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (got kind of red around the shot area after getting the second booster) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Apr-2022, the patient experienced VACCINATION SITE ERYTHEMA (got kind of red around the shot area after getting the second booster). At the time of the report, VACCINATION SITE ERYTHEMA (got kind of red around the shot area after getting the second booster) outcome was unknown.  Concomitant medication information was not provided.  On 14-Apr-2022, the patient received the second booster dose of the vaccine. The patient had not taken any treatment medication for the side effects. The patient was on other daily medications but declined to provide information. The patient did not have any other problems. The patient would like to know if it was normal for the patient to experience the event or not. Reporter did not allow further contact.  Most recent FOLLOW-UP information incorporated above includes: On 18-Apr-2022: Live follow-up document received contains no new information.
Pt came to pharmacy stating a mild rash on left arm, a lump in elbow crease area, redness where injection admin., warmth to area and mild swelling. She was going to call her physician as well.
12-3-13 vac given. Mom noticed swelling (L) thigh 12-4-14. 12-5-14 brought in to see MD. ZYRTEC 5m/5ml tx 2 1/2 ml PQ Q24 hours PRN 12-5-14 KEFLEX 250 mg/5mL-Txc 2 1/2 mls PQ TID x 10 days
Severe pain 8/10 developed that night in left upper arm. Unable to lift arm above head. No swelling, bruising or discoloration. Pain still present.
Inappropriate schedule of vaccine; elevated ALT; Drug dose administration interval too long; This case was reported by a consumer via call center representative and described the occurrence of alanine aminotransferase increased in a 66-year-old female patient who received HAB (Twinrix) for prophylaxis.   Co-suspect products included HAB (Twinrix) for prophylaxis and Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on unknown date.).   On 22nd April 2019, the patient received the 1st dose of Twinrix (intramuscular) 1 ml. On 30th May 2019, the patient received the 2nd dose of Twinrix (intramuscular) 1 ml. In December 2018, the patient received the 2nd dose of Shingrix. In December 2018, not applicable after receiving Twinrix and Twinrix and unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On 23rd May 2019, the patient experienced alanine aminotransferase increased. On 30th May 2019, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the alanine aminotransferase increased, drug dose administration interval too long and drug dose administration interval too long were unknown.   It was unknown if the reporter considered the alanine aminotransferase increased to be related to Twinrix.  Additional details were provided as follows: On 22nd April 2019, the patient received the 1st dose of Twinrix. Around 23rd to 24th May 2019, she had bloodwork done and it showed her Alanine aminotransferase increased elevated to 44. The preferred range on the test was 6 to 29. Her Alanine aminotransferase increased tends to run a little high, but at 30 to 31, not as high as 44.  On 30th May 2019, she received her 2nd dose of Twinrix, which was past 1 month for the 2nd dose, which led to lengthening of the vaccination schedule. The reporter, previously received Shingrix and got her 2nd dose in December 2018, and it was 2 to 3 weeks past 6 months, which led to lengthening of the vaccination.  The reporter consented to follow up.      Lab Comments: On unknown date, the test ALT tends to run a little high, but at 30 to 31
25AUG between 9 & 11PM cried not high pitched but inconsolable for 2hr;had been given Advil dose a/episode;mom talked w/MD who suggested not to get pertussis next dose;
Information has been received from a physician's assistant concerning a 38 year old female with seasonal allergy and no pertinent medical history who on 11 Sep 2006 was vaccinated intramuscularly with a 0.5ml dose of HPV vaccine (lot #653650/0702F). Concomitant therapy included COMBIVENT and CLARITIN D. The patient reported that within days after 11 Sep 2006, she had to use her inhaler on and off since then. The patient called the physician's office and reported a runny nose and stuffiness since the vaccination with symptoms that continued. The patient took allergy medicine and inhaler without relief. The patient sought unspecified medical attention. At the time of the report, the patient had not recovered. In follow-up it was reported by the physician's assistant that the patient had generalized shortness of breath on 10-NOV-2006. The patient needed to use her inhaler, which she had not needed to do in over two years. The patient reported that she did not get any relief from loratadine (+) pseudoephedrine sulfate. At the time of the report, it was unknown, if the patient recovered.
PATIENT FEELS DIZZY, LEFT ARM WHERE SHOT GIVEN HAS MEDIUM SIZE REDNESS AND SWELLING.
It was reported that a pt was vaccinated with Tripedia on 9/5/02. On 9/6/02, the pt was presented to the Dr's office with a fever of 99.4F, which later went to 101.0F. The pt complained of feeling faint so the doctor sent him to the ER and was discharged when they could not find anything wrong with him. The administering nurse discovered that the vaccine was expired by 12 days when given (expiration date 24/Aug/2002).
Patient is currently experiencing numbness in her upper and lower arm and outer 3 fingers on left hand. Had flu shot on 11-2-17 and started experiencing the numbness the next day. Has seen Dr. on 1-19-18 and he prescribed prednisone 20mg. First reported this to us at our pharmacy today, 1-19-2018.
Shingrix never got the second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix  (1st dose received on 2020 from lot number 7AS54 and expiry date 15th May 2022).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: Shingrix never got the second dose). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 21-SEP-2023 The reporter asked if the patient needs to restart the series. Till the time of reporting, the patient did not receive the 2nd dose, which led to incomplete course of vaccination. The reporter consented to follow up.
Vaccine was administered subcutaneously hence an possible efficacy failure.  Nurse painfully pinched arm skin to administer COVID vaccine into pinched area. Second shot was administered 4/17 and sore arm was the only side effect (consistent with known effects expected of first shot).  Am concerned I am at risk having essentially only received only one correctly administered shot.  Note: "Injecting a vaccine into the layer of subcutaneous fat with poor vascularity resulting in slow mobilisation and processing of antigen leading to vaccine failure."
JOINT PAIN; FATIGUE; INJECTION SITE PAIN; CHILLS; FEVER; This spontaneous report received from a patient concerned a 72 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included asthma, high blood pressure, and allergy. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808980, and expiry: UNKNOWN) dose was not reported, administered on 06-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 06-APR-2021, the subject experienced chills. On 06-APR-2021, the subject experienced fever. On 08-APR-2021, the subject experienced injection site pain. On 11-APR-2021, the subject experienced joint pain. On 11-APR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from chills on 06-APR-2021, and fever on 08-APR-2021, and had not recovered from fatigue, injection site pain, and joint pain. This report was non-serious.
3 weeks after getting the Johnson and Johnson covid19 vaccine I started having problems breathing. It continued to worsen and then my doctor ordered a d-dimer test which showed I had blood clots. Sent to the emergency room and they found multiple blood clots in my lungs. Was kept overnight and started on blood thinners.
Circumferential edema, erythema and heat 3 inch above left elbow to axillary line.
Apprx. 10 minutes after varicella immunization was given in left thigh, pt began crying loudly and a red, edematous area began formatting around site of varicella injection. Pt was given 12.5mg Benadryl IM and cool compresses applied to site.
pt wouldn't stand on rt leg-mom put pt in tub of warm water;pt dressed & given bottle laid on floor-seemed helpless & crying;pt exp chills & eyes glassy & staring;purple color;threw up;poss febrile sz feel pertussis was the problem
While in waiting room patient developed sensation of throat closing. paramedics called -> administered 1 dose epinephrine and taken to hospital. initially felt better -then developed throat closing sensation again. ER noted possible uvular edema so administered 2nd dose of epi as well as steroids, albuterol. Monitored overnight - no further recurrence.
Idiopathic Inflammatory Myositis w/ new-onset same month of receiving the second dose, Unintentional 7 lbs weight loss in past 2 months.  Tingling/cramping sensation in both hands. Weakness in upper and lower extremities, difficulty opening bottles, doing push-ups, fully extending his fingers and wrists, standing up and walking up stairs. Difficulty swallowing both solids and liquids, speech becoming softer and changed in quality. Pain in both arms. 2-day hx of dark urine when admitted on 8/31. Hospitalization, steroids, IVIG, methotrexate, and physical therapy  The patient has continued distal and proximal weakness, is unable to complete activities of daily life, and requiring continued treatment at this time.
pt recv vax 18SEP96 & same day pt face was flushed & poss had a fever;pt plans to call allergist;sx persisted as of 18SEP96;
Began with chills, increasing in intensity after 2 hours or so, followed by high body temperature, aching joints, nausea (vomiting just prevented by self control around 11 PM) and accompanied by disorientation and confusion toward the end of the reaction (12-2 AM). Symptoms began to recede by 2 or 3 AM, leaving a lingering headache behind the eyes; took 650 mg acetaminophen. By late morning (10/15/2015) was back more or less to normal. Having had flu in past years, I can describe the symptoms here as equivalent to a 2-3 day flu episode compressed into a few hours: chills, high temperature, some aching joints and nausea.
Area 6.5cmx6.5cm mild erythema and induration. Rx Keflex.
The pt experienced nausea, redness, itching and irritation at injection site. Pt also had eye redness with matting. Discussed with mom the possibility that the eyes were not immunization related.
Bursitis on site of injection; Injection was given too high on shoulder; Restricted movement on injection site; redness on injection site; A spontaneous report was received from a physician concerning a 63-year-old, female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) too high on the shoulder (product administered at inappropriate site) and developed bursitis and redness on injection site (vaccination site erythema) and restricted movement (vaccination site movement impairment).   The patient's medical history was not provided. Products known to have been used by the patient, within two weeks prior to the event, was not reported.  On 19 Feb,2021, prior to the onset of the event, the patient received their second of two planned doses of mRNA-1273 (Lot unknown) intramuscularly in the left arm for prophylaxis of COVID-19 infection.   On 19, Feb 2021, the patient received Moderna's COVID-19 Vaccine (mRNA-1273) too high on the shoulder and developed bursitis and redness on injection site and restricted movement. Treatment for the event was not provided.    The patient received both scheduled doses of mRNA-1273 prior to the event(s); therefore, action taken with the drug in response to the event(s) is not applicable.  The outcome of the event, vaccine was given too high on the shoulder, was considered resolved. The outcome of the events, developed bursitis and redness at the injection site and restricted movement, were considered unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events a causal relationship cannot be excluded.
Swelling at site, red dots, bruising, consistent unrelenting  itching for one and a half weeks
Information has been received from a nurse practitioner concerning a female patient who, on an unspecified date, was vaccinated with a dose of GARDASIL (dose and lot number not reported). Concomitant therapy included meningococcal vaccine (unspecified). The nurse reported that "the patient was administered a dose of the vaccine, which dose was unspecified". It was reported that right after receiving the vaccination "about a month ago" the patient was lying down in the office and when she went to get a glass of water she passed out. The patient was also showing "seizure-like" activity". The patient sought for unspecified medical attention. Upon internal review, seizure-like activity was determined to be an other important medical event. Additional information has been requested.
PASSED OUT AFTER THE SHOTS FOR FEW SECONDS IN THE WAITING ROOM. GAVE HIM WATER AND JUICE. WATCH AND EXAMINED BY DR. GLUCOSE, PULSE OX AND TEMPERATURE WAS COMPLETED AND AT NORMAL LEVELS WAS ALLOWED TO LEAVE PER DR WHEN CHILD FELT GOOD.
Within minutes of receiving vaccines pt developed a very pronounced rash from thighs where injections were given down to ankles. Rash was blanchable, red to purple in color, some raised bumps, some flat. Covering entire legs. Resolved on own over about 6 hours.
All starting around 6:00 PM the same day Chills Fatigue  Headache  Sore arm Red raised injection site
PATIENT PRESENTED WITH REDNESS/RASH AND SWELLING AROUND BICEP OF ARM AND COMPLAINED OF SORENESS OF ARM AND AT SITE OF INJECTION.
left ear fullness 1327pm left throat fullness 1328pm Nausea 1328pm sent to emergency room/arrived at emergency room 1330 symptoms increased.  airway not obstructed.  No tongue swelling reported by MD.  Light red rash/flushing on chest. 25mg IV benadryl administered.  IV Solumedrol administered, Vital signs stable. Cardiac monitor: regular rate and rhythm. O2 saturations 98% on room air.  Symptoms improving at 1345pm.  Monitored in emergency room for 1 hour. Discharged in stable condition with instructions to repeat Benadryl 8 hours after first dose if needed Throat fullness ( left side) with mild difficulty swallowing continued. Headache 5pm.  Left sided face fullness/tingling: jaw, cheek. Left eye: mild swelling. 25 mg Po Benadryl taken.    01/06/21 0800 AM symptoms Left sided facial fullness/tingling continues: mild.  No difficulty breathing. Left eye mild/yet decreased puffiness continues.
The first 2 shots were simple, she had a sore arm for a couple days.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 61 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 31Mar2021 (Lot number: EN6208) at the age of 61 years as dose 2, single and administered in arm right, administration date 10Mar2021 (Lot number: EN6208) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Tachycardia" (unspecified if ongoing), notes: Verbatim: super clavicular tachycardia; "Breast cancer" (unspecified if ongoing), notes: Verbatim: Breast cancer, Left Breast. The patient's concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "The first 2 shots were simple, she had a sore arm for a couple days".  Additional information: The first 2 shots were simple, she had a sore arm in 6 to 12 hours for a couple days.   No follow-up attempts are possible. No further information is expected.
Pt with severe local erythema, edema, induration extending circumferentially around (L) upper arm from vaccine site. Area of induration is 28cm in surperior-inferior aspect and 18 cm in medio-lateral aspect.
Baseball/softball sized lymph node swelling in injection arm under armpit less than 48 hrs later.; Fever; body ache; exhaustion; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 43 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 10Nov2021 at 16:45 PM (Lot number: FF2590) at the age of 43 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Lupus" (unspecified if ongoing); "fibromyalgia" (unspecified if ongoing). There were no concomitant medications. Past drug history included: Bo, reaction(s): "Known allergies: Bo". The patient was diagnosed with COVID prior vaccination. The patient was not tested for COVID post vaccination. The following information was reported: LYMPHADENOPATHY (non-serious) with onset 12Nov2021, outcome "not recovered", described as "Baseball/softball sized lymph node swelling in injection arm under armpit less than 48 hrs later."; PYREXIA (non-serious) with onset 12Nov2021, outcome "not recovered", described as "Fever"; PAIN (non-serious) with onset 12Nov2021, outcome "not recovered", described as "body ache"; FATIGUE (non-serious) with onset 12Nov2021, outcome "not recovered", described as "exhaustion". The events "baseball/softball sized lymph node swelling in injection arm under armpit less than 48 hrs later.", "fever", "body ache" and "exhaustion" were evaluated at the emergency room visit. Therapeutic measures were taken as a result of lymphadenopathy, pyrexia, pain, fatigue included antiinflammatory medication.  Follow-up attempts completed. No further information expected.
Received influenza injection on 12/9/11. On 12/10/11 arm (deltoid region) became sore and soreness has migrated to armpit and underarm as well as deltoid. No swelling/redness. Hurts with pressure and hurts to use arm.
Pt. states that after receiving the 2nd dose of Phizer 03/14/2021, started experiencing symptoms that evening of chills, body aches, flu-like symptoms, lasting 24hrs. No noted Primary visit. Symptoms have subsided.
Pt recvd 1 dose of Engerix-B & exp severe local burning & pain, bilateral numbness & tingling in fingers, a sore arm & fatigue; all sx resolved in 24 hrs;